 Study unblinded due to strong efficacy signal for 28-day mortality endpoint Critically ill patients demonstrated a 68.5 reduction in the risk of dying when treated with EB05 over Standard of Care Data monitoring board recommends continuation to confirmatory Phase 3 study TORONTO, ON ACCESSWIRE September 20, 2021 Edesa Biotech, Inc. NASDAQ:EDSA, a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced positive results from the Phase 2 part of an ongoing Phase 23 clinical study evaluating the companys monoclonal antibody candidate, designated EB05, as a single-dose treatment for hospitalized COVID-19 patients. An independent Data and Safety Monitoring Board DSMB, composed of subject matter experts, informed the company that during its initial analysis of the Phase 2 portion of the study they identified an important signal between the treatment arms for 28-day mortality, and requested that the study be preemptively unblinded. 